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Abstract
The power of genome-wide association studies can be improved by incorporating information from
previous study findings, for example, results of genome-wide linkage analyses. Weighted false-
discovery rate (FDR) control can incorporate genome-wide linkage scan results into the analysis of
genome-wide association data by assigning single-nucleotide polymorphism (SNP) specific weights.
Stratified FDR control can also be applied by stratifying the SNPs into high and low linkage strata.
We applied these two FDR control methods to the data of North American Rheumatoid Arthritis
Consortium (NARAC) study and the Framingham Heart Study (FHS), combining both association
and linkage analysis results. For the NARAC study, we used linkage results from a previous genome
scan of rheumatoid arthritis (RA) phenotype. For the FHS study, we obtained genome-wide linkage
scores from the same 550 k SNP data used for the association analyses of three lipids phenotypes
(HDL, LDL, TG). We confirmed some genes previously reported for association with RA and lipid
phenotypes. Stratified and weighted FDR methods appear to give improved ranks to some of the
replicated SNPs for the RA data, suggesting linkage scan results could provide useful information to
improve genome-wide association studies.
Background
Use of prior or additional information may improve the
power of single-nucleotide polymorphism (SNP)-disease
association analysis. In particular, genome-wide linkage
scans can provide complementary information to gen-
ome-wide association studies (GWAS). The weighted
false-discovery rate control (WFDR) method incorpo-
rates genome-wide linkage study results by converting
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scaling the association p-value for each SNP [1]. The
stratified FDR control method (SFDR [2]) prioritizes
genomic regions according to the available linkage
scores. WFDR requires the investigator to choose and
assign weights to SNPs whereas in SFDR, stratum-specific
weights are internally derived by the choice of strata and
the distribution of data [3]. SFDR is designed to use prior
information to assign SNPs into strata that are more or
less likely to include true-positive associations, which
can similarly improve the power of GWAS, but is more
robust than WFDR to uninformative or even misleading
prior information [3]. We applied these two FDR
methods along with the original FDR method to the
North American Rheumatoid Arthritis Consortium
(NARAC) study data provided for Genetic Analysis
Workshop 16 (GAW 16) using previously reported
linkage study results for rheumatoid arthritis (RA) [4].
We also performed genome-wide linkage and association
analyses of the FHS data a n da p p l i e dt h et h r e eF D R
methods. We compared the regions of association
identified by the different methods.
Methods
Samples, phenotypes, and genotypes
RA data
The NARAC data provided for GAW 16 included a set of
868 cases and 1,194 controls with information on a
binary outcome (RA affection status) and on 545,080
genome-wide SNP genotypes from the Illumina 550 k
chip as well as the physical locations for the SNPs. In our
association analysis, RA affection status was defined as
positive for anti-cyclic citrinullated peptide antibody
(anti-CCP).
FHS data
SNP genotyping data were provided based on the
GeneChip Human Mapping 500 k Array and 50 k
Human Gene Focused Panel. We analyzed a combined
sample of the Offspring Cohort (N1 = 2,584) and the
Generation 3 Cohort (N2 = 3,811) for association with
each of the blood lipid measures, high-density lipopro-
tein (HDL), low-density lipoprotein (LDL), and trigly-
ceride (TG), and included all family members in the
sample who had been genotyped and phenotyped. The
mean of lipid measures over multiple exams was
adjusted for age, sex, body mass index (BMI), alcohol
intake, and cigarette smoking. The phenotype measures
of treated people were imputed using the methods in
Kathiresan et al. [5] and Levy et al. [6].
Quality control of SNP data
We excluded SNPs with Hardy-Weinberg equilibrium
p-value ≤ 10
-9in controls, missing genotype rate >5%,
and minor allele frequency <0.01. Samples were also
filtered by individual call missing rate >5%, duplicity,
and relatedness. Within autosomes, there were 490,915
SNPs remaining in the RA data and 430,292 SNPs in the
FHS data after applying this set of quality control criteria,
using the computer program PLINK [7].
Genome-wide association analysis
RA data
Each SNP was tested for association using the 1-df allelic
chi-squared test assuming an additive genotype model,
implemented in PLINK [7].
FHS data
SNP association was evaluated using adjusted residual
mean values obtained from the generalized estimating
equation model for familial correlation. We split
families unconnected in the Offspring and Generation
3 Cohort using the R package “kinship” [8]. Generalized
estimating equation fitting was performed using a SAS
GENMOD procedure assuming an exchangeable working
correlation matrix.
Genome-wide linkage analysis
RA data
Results of the NARAC linkage study of RA using 642
Caucasian families and high-density SNP genotyping, as
reported in Amos et al. [4], were used as the available
prior linkage information, based on RA status (anti-CCP
positivity) as the phenotype. The linkage scores at SNP
markers across the genome, publicly available as
supplementary information, were the nonparametric
linkage (NPL) scores computed by Amos et al. [4]
using linkage disequilibrium (LD) eliminated SNP
genotypes. For the chromosomes with large centromeres
( 1 ,3 ,9 ,1 1 ,1 6 ,a n d1 9 ) ,t h e ya s s u m e dz e r or e c o m b i n a -
tion of the centromeric regions.
FHS data
We performed a genome-wide linkage scan for each of
the three lipid phenotypes values (i.e., covariate adjusted
residuals), using 8,545 individuals from 1,349 FHS
families (3,928 founders, 4,617 non-founders; 4,363
females and 4,182 males; family size ranging from 3 to
19). We selected 5,102 SNPs for the linkage scan
according to the criteria of MAF > 0.45, HWE test
p-values in founders >0.05, individual genotype missing
rate <5%, SNP missing rate <2%, mendelian error rate
<5%, and LD measure r
2 < 0.05 between SNPs. Genome-
wide linkage scans were performed using the regression
methods of MERLIN-REGRESS (version 1.1.2) [9,10]: the
identical-by-descent (IBD) allele-sharing status for all
relative pairs was regressed on the squared differences
and squared sums of the pairs’ trait values. This method
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variance, and heritability. We therefore estimated the
heritability using the variance-components (VC) option
in MERLIN. Lacking an available genetic map, we
interpolated the deCODE map from the Affymetrix,
Inc. website for the 5,102 selected SNPs.
SNP-specific linkage scores
The linkage score corresponding to each of the ~550 k
GWA SNPs, Zi, i =1 ,. . . ,M, was interpolated from the
linkage scores of the available neighboring markers
according to the relative distance between markers.
False-discovery rate control methods
False-discovery rate (FDR) control was performed by
computing q-values using the method suggested by
Storey [11]. If the q-value of a single SNP analysis was
less than the chosen FDR control threshold value, the
hypothesis of no association between the SNP and the
disease was rejected.
Stratified FDR
Based on the linkage scan results, high and low linkage
regions were determined using a NPL threshold value of
C = 1.64 for the NARAC RA data and LOD threshold
value C = 0.5 for the FHS data. SNPs that fell into a high-
linkage region were grouped as Stratum 1 (Zi ≥ C)a n d
SNPs that fell into a low-linkage region were grouped as
Stratum 2 (Zi <C). FDR control was applied separately
for the SNPs in Stratum 1 and Stratum 2 [11].
Weighted FDR
The weight of each SNP was obtained as wi = exp(B·Zi)/
v,w h e r evB Z M i i
M
=⋅ ∑ exp( )/ and B = 1 (exponential
weighting [1]). FDR was applied to weighted p-values,
pj/wj, and the corresponding q-values were computed.
Results
Results of the RA data analysis
The SNPs in chromosome 6 (MHC region) showed very
strong association with p-values less than 10
-100 and also
very high linkage scores (NPL>16). To focus on results
outside regions of established importance, Table 1
excludes chromosome 6 SNPs and presents results of
SNPs with ranks ≤ 10 based on any of FDR methods or
SNPs from genes previously reported to be associated
with RA [12-14]. Most of the latter were ranked higher
than other SNPs in the genome. For some SNPs, mostly in
the stronger linkage regions, either SFDR or WFDR
improved the rank more than the other. For example,
the original rank of rs1018361 in CTLA4 was 285 using
FDR, which changed to 28 and 96using SFDR and WFDR,
respectively. In some weak linkage regions (TRAF1,
WDFY4), WFDR retained similar ranks as FDR, whereas
the SFDR ranks increased. However, q-values for WFDR
were generally much higher than those of FDR and SFDR
Table 1: Results of FDR, SFDR, and WFDR analyses of selected SNPs for the RA phenotype from the NARAC study
SNP
a Chr BP Gene Association
p-value
Rank Linkage
NPL score
c
FDR SFDR WFDR
rs6683201 1 17426583 PADI4
b 1.32 × 10
-3 3531 4172 5320 -0.11
rs2476601 1 114089610 PTPN22
b 2.91 × 10
-12 11 1 0 . 1
rs2542941 2 172235228 CYBRD1 4.25 × 10
-6 69 5 36 1.76
rs6433309 2 172343658 No gene 1.50 × 10
-6 35 2 21 1.74
rs13031008 2 178302621 TTC30A 8.13 × 10
-6 121 11 38 2.24
rs12693591 2 191686008 STAT1
b 3.98 × 10
-2 39083 15997 5028 3.38
rs6752770 2 191799069 STAT4v 7.28 × 10
-3 11404 2787 1554 3.42
rs10184573 2 200273759 No gene 5.63 × 10
-6 84 6 22 2.93
rs1018361 2 204510341 CTLA4
b 3.36 × 10
-5 288 28 98 2.14
rs6596147 5 133075674 No gene 4.61 × 10
-9 38 4 0 . 1 6
rs6978820 7 146629802 CNTNAP2 2.22 × 10
-6 46 3 24 1.79
rs2900180 9 120785936 TRAF1
b 3.08 × 10
-9 27 3 0 . 0 1
rs7037673 9 120820038 C5
b 2.15 × 10
-5 212 400 306 0.01
rs2671692 10 49767825 WDFY4 2.66 × 10
-8 10 18 10 0.28
rs1182531 20 57826397 PHACTR3 4.83 × 10
-9 49 2 0 . 5 8
rs9974986 21 35262686 RUNX1
b 3.79 × 10
-3 7246 8165 6401 0.68
rs713756 22 43118847 No gene 2.10 × 10
-8 9 17 8 0.08
aThe SNPs listed in the table include the most significant SNP from each of the previously reported genes and SNPs with ranks ≤ 10 (one SNP per
region) based on any of the FDR methods.
bGenes previously reported to be associated with RA.
cGenome-wide linkage NPL scores ≥ 1.64 (the chosen SFDR threshold) are in bold.
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associations with RA (e.g., CNTNAP2 on chromosome 7).
Results of the FHS data analysis
Table 2 presents the results of SNPs selected with ranks ≤
10 based on any of the three FDR methods or those most
significant among genes previously reported for associa-
tion with TG [5,15]. All SNPs with rank ≤ 10 resided in
the previously reported genes. SNPs in stronger linkage
regions showed improvement in rank using SFDR and
WFDR (linkage scores in bold). However, some of the
gene regions previously reported for TG, HDL, or LDL
were not confirmed in the FHS samples.
Discussion
The SFDR and WFDR methods can improve power of
genome-wide association analyses when linkage scans
are informative [1,3]. In the RA and FHS studies, using
SFDR and WFDR improved ranks of SNPs in new and
previously reported regions, suggesting improved power.
The threshold value for Stratum 1 and 2 in SFDR was
somewhat arbitrarily set as 1.64 for the RA data (where
the linkage results were NPL scores) and 0.5 for the FHS
data (where the linkage results are LOD scores) to
maintain the proportion of Stratum 1 to be about 5%
when the power of linkage scans is relatively low. The
effect of small differences in threshold values for SFDR
was insignificant on average in a simulation study [3]. In
the RA and FHS data sets, the choice of different
thresholds did produce some differences in ranking
values, but the effect was minimal.
The power under FDR control depends on the proportion
of true alternative hypotheses (true causal SNPs) in a
family of tests. By preserving most of the potentially true
causal SNPs in a small-sized Stratum 1, we can improve
study power [3]. However, how to choose this threshold
to optimize power remains an open question. A similar
question applies to the choice of the weighting scheme
(i.e., the value of the B parameter) for the WFDR method.
SFDR and WFDR control methods using previous
linkage results can be extendedt om u l t i - m a r k e ra n a l y s i s
with fixed or sliding windows, for example, by using the
average linkage score within a window as a measure of
prior information. Further study is warranted to evaluate
extensions to multi-marker analysis settings.
List of abbreviations used
Anti-CCP: Anti-cyclic citrinullated peptide antibody; BMI:
Body mass index; FDR: False-discovery rate; GAW: Genetic
Analysis Workshop; GWAS: Genome-wide association
studies; HDL: High-density lipoprotein; IBD: Identical by
descent; LD: Linkage disequilibrium; LDL: Low-density
lipoprotein; NARAC: North American Rheumatoid Arthritis
Consortium; NPL: Nonparametric linkage; RA: Rheumatoid
arthritis; SFDR: Stratified false-discovery rate control
method; SNP: Single-nucleotide polymorphism; TG: Trigly-
ceride; VC: Variance-component; WFDR: Weighted false-
discovery rate control.
Table 2: Results of FDR, SFDR, and WFDR analysis of selected SNPs for the TG phenotype from the FHS study
SNP
a Chr BP Gene
b Association
p-value
Rank Linkage
LOD score
c
FDR SFDR WFDR
rs4350231 1 62695248 DOCK7 2.39 × 10
-3 2376 2953 2755 0.11
rs4846918 1 228367209 GALNT2 2.00 × 10
-2 14171 9915 10990 0.56
rs780094 2 27594741 GCKR 2.83 × 10
-10 18 16 16 1.1
rs6731583 2 202269099 ALS2 9.12 × 10
-2 52483 55094 66274 0
rs16872759 4 22118656 GPR125 6.90 × 10
-3 5805 6490 6951 0.05
rs1178977 7 72494985 BAZ1B 2.17 × 10
-12 10 12 10 0
rs17145738 7 72620810 TBL2 1.28 × 10
-10 15 19 18 0
rs17411031 8 19896590 LPL 1.23 × 10
-17 112 0.91
rs2980875 8 126550929 TRIB1 1.74 × 10
-9 21 24 21 0.38
rs6475522 9 2120917 SMARCA2 1.62 × 10
-2 11891 7794 5774 1.14
rs3750929 11 82259235 PRCP 1.73 × 10
-1 92300 96678 115272 0
rs6589566 11 116157633 APOA5 1.71 × 10
-12 9 11 9 0.02
rs948028 11 120149657 GRIK4 1.80 × 10
-3 1899 2234 1986 0.23
rs2451214 17 78308343 TBCD 1.98 × 10
-1 103764 108501 129319 0
rs3813136 19 15452333 PGLYRP2 7.23 × 10
-1 333987 276706 250668 0.51
rs2424295 20 20165327 C20orf26 2.30 × 10
-2 15945 17260 18677 0.09
aThe SNPs listed in the table include the most significant SNP from each of the previously reported genes and SNPs with ranks ≤ 10 (one SNP per
region) based on any of the FDR methods.
bAll genes listed were previously reported to be associated with RA.
cGenome-wide linkage LOD scores ≥ 0.5 (the chosen SFDR threshold) are in bold.
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